Cost comparison of controlled ovarian stimulation with rFSH-alfa and rFSH-beta using a pen-device

    Research output: Contribution to journalArticleResearchpeer-review

    2 Citations (Scopus)

    Abstract

    This study compares the pharmaceutical costs of ovarian hyperstimulation with either rFSH-alfa or rFSH-beta, using a pen device, in the most common settings of clinical practice in Spain. For this purpose, in the first place, protocols commonly used for the treatment of IVF/ICSI and IUI patients were reflected with decision trees, showing starting rFSH doses and their possible subsequent modifications, the probability of making these modifications, and the duration of the treatment. These decision trees were then used to calculate the expected costs of a treatment cycle for each of the protocols and each of the two drugs. For all analyzed protocols the expected cost turned out to be lower for rFSH-beta. Depending on the specific protocol, the difference in cost per cycle lay between €43 and € 292€ implying potential savings on drug costs of 6.8% to 17.5% when using rFSH-beta instead of rFSH-alfa.
    Original languageEnglish
    Pages (from-to)399-411
    JournalRevista Iberoamericana de Fertilidad y Reproduccion Humana
    Volume27
    Issue number5
    Publication statusPublished - 1 Sep 2010

    Keywords

    • Assisted reproduction
    • Cost-effectiveness
    • FSH
    • Optimal prescription
    • Ovarian stimulation

    Fingerprint Dive into the research topics of 'Cost comparison of controlled ovarian stimulation with rFSH-alfa and rFSH-beta using a pen-device'. Together they form a unique fingerprint.

    Cite this